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Background. The immune deﬁciency of human immunodeﬁciency virus (HIV) infection is not fully corrected
with ARV therapy. Interleukin-7 (IL-7) can boost CD4 T-cell counts, but optimal dosing and mechanisms of
cellular increases need to be deﬁned.
Methods. We performed a randomized placebo-controlled dose escalation (10, 20 and 30 µg/kg) trial of 3
weekly doses of recombinant human IL-7 (rhIL-7) in ARV-treated HIV-infected persons with CD4 T-cell counts
between 101 and 400 cells/µL and plasma HIV levels <50 copies/mL. Toxicity, activity and the impact of rhIL-7
on immune reconstitution were monitored.
Results. Doses of rhIL-7 up to 20 µg/kg were well tolerated. CD4 increases of predominantly naive and central
memory T cells were brisk (averaging 323 cells/µL at 12 weeks) and durable (up to 1 year). Increased cell cycling
and transient increased bcl-2 expression were noted. Expanded cells did not have the characteristics of regulatory or
activated T cells. Transient low-level HIV viremia was seen in 6 of 26 treated patients; modest increases in total
levels of intracellular HIV DNA were proportional to CD4 T-cell expansions. IL-7 seemed to increase thymic output
and tended to improve the T-cell receptor (TCR) repertoire in persons with low TCR diversity.
Conclusions. Three weekly doses of rhIL-7 at 20 µg/kg are well tolerated and lead to a dose-dependent CD4
T-cell increase and the broadening of TCR diversity in some subjects. These data suggest that this rhIL-7 dose could
be advanced in future rhIL-7 clinical studies.
Clinical Trials Registration. NCT0047732.
Interleukin 7 (IL-7), a cytokine produced by lymph
node and thymus stromal cells, has profound effects
on human and murine T-cell homeostasis [1]. IL-7 is
required for thymic T-cell development in the thymus
and also promotes postthymic T-cell survival, prolifer-
ation and maturation (reviewed in [2]).
The heterodimeric IL-7 receptor (IL-7R) comprises a
cytokine binding IL-7Rα chain and a signaling common
γ chain (γc) shared by other cytokine receptors [3]. The
IL-7R is expressed by lymphocyte precursors, developing
thymocytes, and mature T cells. Patients with mutations
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conﬁrming that IL-7 is essential for human T-cell development.
This is supported by the inverse relationship between circulating
IL-7 levels and peripheral CD4 T-cell numbers consistently
found in lymphopenic states, including human immunodeﬁcien-
cy virus (HIV) infection [5, 6]. Nonhuman primate studies
showed that IL-7 administration was safe and had a signiﬁcant
impact on T-cell homeostasis [7–10],including T-cell trafﬁcking
and proliferation in the gut mucosa [11]. In humans, phase I
HIV and cancer studies demonstrated the safety and biologic ac-
tivity of single or repeated doses of nonglycosylated recombinant
human IL-7 (rhIL-7) [12–15]. With a favorable safety proﬁle,
rhIL-7 was shown to increase circulating numbers of both naive
and memory CD4 and CD8 T cells. However, the most well-
tolerated biologically active dose of rhIL-7 that could be applied
in phase IIb/III studies still remains unclear [16,17]
We report a phase I/IIa dose escalation study of repeated
administration of a glycosylated rhIL-7 in HIV-1–infected
patients whose CD4 T-cell counts failed to normalize despite
virologic suppression with antiretroviral (ARV) therapy. The
study objectives were to identify an optimal dosing regimen
for phase IIb/III studies in HIV disease based on toxicity
and efﬁcacy and to further evaluate mechanisms of T-cell
restoration with rhIL-7 therapy.
SUBJECTS AND METHODS
Subjects
Eligible subjects were chronically HIV-1–infected patients
with CD4 T-cell counts of 101–400 cells/µL and plasma HIV
RNA levels <50 copies/mL for ≥6 months while receiving
ARV therapy for >12 months. Acceptable ARVs included any
protease inhibitor (with or without ritonavir) or any non-
nucleoside reverse-transcriptase inhibitor combined with 2
nucleoside reverse-transcriptase inhibitors.
Recombinant Human IL-7
CYT107 is puriﬁed glycosylated 152 amino acid rhIL-7
expressed in a Chinese hamster ovary (CHO) cell line.
Study Design and End Points
A randomized, placebo-controlled, single-blind, interpatient,
dose escalation design was chosen to facilitate the replacement
of subjects as needed and also because injection site reactions
would unblind study staff. The study was approved by ethics
committees or institutional review boards of all participating in-
stitutions in France, Italy, United States, and Canada and was
registered in the EudraCT database (http://eudract.emea.eu/;
protocol 2006–00624-20A) and at clinicaltrials.gov (NCT0047732),
IND 100538, and CTA 9427-C2666/1-21C. All participants
signed written informed consent before enrollment.
The subjects received 3 weekly subcutaneous (SC) injections
of rhIL-7 on days 0, 7, and 14. Three different doses of CYT107
—10, 20, and 30 µg/kg—were tested sequentially. Ten patients
(8 receiving rhIL-7, 2 receiving placebo (sodium chloride)) were
randomized in each dose group and were seen on days 0, 7, 14,
21, 28, and 35, weeks 9 and 12, and then quarterly until week
52. The primary end point was safety, which was assessed
through the reporting of adverse events using the Division of
AIDS (December 2004) toxicity grading scale. Dose-limiting
toxicity was deﬁned as any grade 3 or 4 adverse event, a rash of
grade ≥2, or an immune restoration inﬂammatory syndrome
event; a conﬁrmed increase in plasma HIV RNA levels to
>0.75 log10 copies/mL on day 28 or 35; detection of plasma IL-
7 neutralizing antibodies at dilutions ≥1:400; any diagnosis of
lymphoma; or adenopathy compromising or threatening organ
function. Secondary end points included changes from baseline
in CD4 and CD8 T-cell counts (the baseline was deﬁned as the
mean of 4 values, including 2 obtained in the 6 months prior
to study entry, the initial screening value, and the day 0 value).
Immunophenotyping
Flow cytometric analyses were performed on cryopreserved
peripheral blood mononuclear cells (PBMCs). Labeled cells
were acquired with an LSRII cytometer and analyzed using
DiVa software (Version 6.0). Nine T-cell subsets (Supplemen-
tary Table 1) and phenotypes were deﬁned using the following
antibodies: CD3-AmCyan, CD4-PB, CD8-PerCP-Cy5.5,
CD45RA-ECD, CD27-APC-Alexa-750, CCR7-PE-Cy7, CD31-
FITC, CD127-Alexa-647, PD-1-PE, Bcl2-FITC, HLA-DR-
Alexa-700, CD38-FITC, Foxp3-Alexa700, and Ki-67-FITC.
T-Cell Receptor Excision Circle Quantiﬁcations
Parallel quantiﬁcation of sj T-cell receptor excision circles
(TRECs) and each of the 13 DJβ TRECs, together with the
CD3γ gene (used as a housekeeping gene), was performed
using LightCycler technology (Roche Diagnostics), as de-
scribed elsewhere [18]. The sj/β TREC ratio was calculated as
described elsewhere (sj/β TREC = sj TREC/10
5 cells)/(DJβ1
TRECs/10
5 cells +DJβ2 TRECs/10
5 cells).
Repertoire Diversity
The T-cell receptor (TCR) repertoire was measured using the
ImmunTraCkeR test (ImmunID Technologies) and diversity
(Divpenia and NDL score) was analyzed using Constel’ID soft-
ware (ImmunID). Brieﬂy, 5 × 10
6 PBMCs were thawed and re-
suspended in EasyID buffer containing proteinase K. Multiplex
polymerase chain reaction (PCR) analysis was performed on
the genomic DNA, as described elsewhere [19,20].
HIV DNA Quantiﬁcation
HIV-1 DNA was quantiﬁed in whole blood obtained at day 0,
day 28, and week 12 using a real-time PCR method [21].
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6 CD4 T lympho-
cytes using lymphocyte, monocyte, and CD4 T-cell counts,
according to the following formula: [HIVDNA (copies/10
6
CD4 T cells) =HIV DNA (copies/10
6 PBMCs) ×(PBMCs/µL)/
CD4 T cells/µL)]. HIV DNA levels were also calculated in
copies per mL of whole blood: [HIV DNA (copies/mL whole
blood) =(HIV DNA (copies/10
6 PBMCs) ×(lymphocytes/µL
+monocytes/µL)/1000].
Statistical Analysis
All patients who received ≥1 injection were included in safety
analyses. Immunologic activity was evaluated in patients who
received all 3 weekly administrations. Changes in CD4 T-cell
counts were calculated as absolute values, whereas changes in
marker expression were reported as fold changes from baseline
using the Wilcoxon test for paired samples. Statistical analysis
was performed with SAS software, version 9.2 (SAS Institute).
RESULTS
Study Design and Subjects
Forty-seven subjects were screened, and 32 were enrolled (10,
12, and 10 in the 10, 20, or 30 µg/kg groups, respectively)
(Supplementary Figure 1). The baseline characteristics are
listed in Table 1. Overall, 6 patients received placebo (2 in
each dose group). At 10 µg/kg, 7 subjects received 3 injections
each, and 1 subject received a single injection. At 20 µg/kg,
8 of 10 subjects received 3 injections, and 2 discontinued
treatment after 1 or 2 injections (the ﬁrst because the total
dose was given in a single administration and the second
because of a dispensing error). At 30 µg/kg, 6 of 8 subjects
received 3 injections, and 2 received 1 injection because of a
dose-limited toxic event after the ﬁrst injection. All subjects
completed the study follow-up.
rhIL-7 Induction of Dose-Dependent Sustained Increase in T
Lymphocytes
The subjects in the 10, 20, and 30 µg/kg and placebo groups
had baseline CD4 T-cell counts of 268, 240, 276, and 280
cells/µL, respectively. At week 12, CD4 T cells were 419, 563,
799, and 259 cells/µL (P<.002 representing changes from
baseline for each dose group compared with placebo)
(Figure 1A). Increases were dose dependent (+188, +323, and
+551 cells/µL, respectively). CD8 T-cell counts were 761, 659,
415, and 502 cells/µL at baseline in the 10, 20, and 30 µg/kg
and placebo groups and at week 12, increased to 1081, 1210,
1011, and 487 cells/µL, respectively (Figure 1B)( P<.002 rep-
resenting changes from baseline for each dose group, com-
pared with placebo). At week 52, CD4 T-cell counts remained
signiﬁcantly higher than baseline in all rhIL-7 dose groups
(change, +154, +172 and +209 cells/µL, respectively; all P
<.005). CD8 T-cell counts also remained signiﬁcantly higher
in rhIL-7–treated subjects compared with baseline (P<.01).
A biologically active dose was deﬁned as one that induced a
CD4 T-cell increase of ≥50% above baseline at week 12 in 6 of
8 treated subjects. Both the 20 and 30 µg/kg doses were biolo-
gically active. The median time to reach a threshold of CD4
T-cell count of 500 cells/µL at all doses of rhIL-7 was 14 days;
and at week 12, 62.5% (5 of 8 subjects) and 100% (6 of 6 sub-
jects) in the 20 and 30 µg/kg groups maintained a CD4 T-cell
count >500 cells/µL (data not shown).
Table 1. Baseline Participant Characteristics by Dose Group
rhIL-7 Treatment
Characteristic 10 µg/kg (n=8) 20 µg/kg (n=10) 30 µg/kg (n=8) Placebo (n=6)
Age, years 43 (27–66) 42 (35–52) 49 (41–52) 53 (48–59)
Male-female ratio 5:3 9:1 8:0 3:3
Time since HIV diagnosis, years
a 5( 2 –22) 5 (2–8) 21 (19–23) 14 (3–24)
Duration of ARV, years
a 4( 1 –16) 1 (1–3) 6 (1–15) 9 (3–17)
T-cell counts, cells/µL
CD4
b 268 (152–373) 240 (197–323) 276 (207–370) 280 (203–344)
CD8
c 761 (530–857) 659 (376–1090) 415 (209–1524) 502 (393–1123)
Nadir CD4 100 (10–278) 98 (8–206) 128 (8–254) 45 (5–210)
CD4/CD8 ratio 0.35 (0.18–0.62) 0.39 (0.18–0.64) 0.5 (0.19–1.45) 0.50 (0.17–0.80)
Proviral HIV DNA, log10 copies/10
6 CD4 cells 3.65 (2.79–4.20) 4.04 (3.27–4.41) 3.13 (1.69–4.33) 3.37 (3.05–3.50)
Except for the sex ratios, all values represent medians (ranges). There were no significant differences between groups in any of the listed variables. All subjects
had plasma HIV RNA levels <50 copies/mL.
Abbreviations: ARV, antiretroviral; HIV, human immunodeficiency virus; rhIL-7, recombinant human interleukin 7.
a Derived data.
b The baseline CD4 T-cell count was defined as the mean of 4 values, 2 in the 6 months prior to study entry, 1 at screening, and 1 at day 0.
c The baseline CD8 T-cell count was defined as the mean of results at screening and at day 0.
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Populations
We next investigated the phenotype of the rhIL-7–expanded T
cells. We found a dose-dependent effect of rhIL-7 on both naive
and central memory CD4 T cells at day 28 that remained
signiﬁcantly different from baseline at week 12 (day 77) in
groups treated with the 2 highest doses (P<.0 5)(F ig u r e1C and
1D). Less-pronounced effects were seen for effector memory and
terminal effector memory cells (data not shown). IL-7 effects
were substantially more pronounced on naive than on memory
Figure 1. Changes in T-cell counts after recombinant human interleukin 7 (rhIL-7) administration. A, B, CD4 (A) and CD8 (B) T-cell counts (median,
Quarter 1–Quarter 3) increased signiﬁcantly at week 12 (day 77) after a rhIL-7 cycle (1 injection weekly for 3 weeks) (P<.002, representing changes
from baseline for each dose group compared with placebo). The increase was dose-dependent for both CD4 and CD8 T cells and remained signiﬁcant at
week 52 (P<.005 and P<.01 for CD4 and CD8, respectively). C–F, Naive and central memory CD4 and CD8 T-cell subsets increased after rhIL-7
administration (P<.05 represents comparisons between the 20 and 30 µg/kg dose groups and placebo group by Wilcoxon rank sum test). G, Administra-
tion of rhIL-7 increased absolute counts of regulatory T cells (Tregs), but their frequency was signiﬁcantly decreased. Abbreviations: CM, central
memory; N, naive.
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signiﬁcance in both subsets on days 28 and 77 (P<.0 5)
(week 12).
Recent results of interleukin 2 (IL-2)–based therapy trials
in HIV-infected patients have raised concerns that the
phenotypes of expanded CD4 cells [22] and regulatory
T cells (Tregs) have similar features [23, 24]. In the current
study, CD4 expansion also transiently increased the absolute
numbers of Tregs (CD4
+CD25
+CD127
−FoxP3
+) in all treated
groups on day 28 (P<.001) (Figure 1G). However, the relative
frequency of Tregs decreased signiﬁcantly in the rhIL-
7–treated subjects at day 28 (P=.0005 compared with placebo)
(Figure 1G), as other CD4 subsets had greater expansions.
Effects of rhIL-7 Administration on Markers of T-Cell
Homeostasis
Compared with the placebo group, all doses of rhIL-7 in-
creased the frequency of Ki-67 expression among naive,
central memory, and effector memory CD4 T cells (pooled
groups, all P<.001 at day 7) (Figure 2A). This effect peaked
on day 7, after 1 dose of rhIL-7 in each group. A similar effect
of rhIL-7 was noted among CD8 T-cell subsets (Figure 2A).
This effect was not dose dependent, and the frequency of
cycling T cells returned to baseline on day 28 in all groups
(Figure 2A). As shown elsewhere in cancer patients [15], a
signiﬁcant transient increase in CD4 and CD8 T cells express-
ing Bcl-2 was observed during rhIL-7 therapy (at days 7 and
14 for pooled rhIL-7 groups, P<.001); these counts subse-
quently returned to values lower than baseline (P<.001 at
week 12 [day 77]) (Supplementary Figure 2).
Effects of rhIL-7 on T-Cell Expression of Programmed-Death 1
The proportion of T cells expressing Programmed-Death 1
(PD-1), a marker of activation or exhaustion in HIV-infected
subjects [25], was also evaluated. As shown in Figure 2B,t h e
frequency of CD4
+PD-1
+ and CD8
+PD-1
+ T cells decreased
signiﬁcantly from baseline (up to a 40% decrease for subjects
treated with 20 or 30 µg/kg rhIL-7; P<.05) for both CD4 and
CD8 and memory T cells at days 28 and 77. Administration of
rhIL-7 did not signiﬁcantly change the frequency of CD4 and
CD8 T cells coexpressing the activation marker CD38
+/DR
+
(Supplementary Figure 3).
Effects of rhIL-7 on Thymocyte Proliferation and the T-Cell
Repertoire
We next quantiﬁed the proportion of recent thymic emigrants
(RTE) among naive CD4 T cells, cells containing T-cell recep-
tor excision circles (TRECs), and TCR diversity using a quan-
titative real-time PCR method. As shown in Figure 3A, for
subjects treated with the highest doses (20 or 30 µg/kg), rhIL-
7 increased both naive and RTE CD4 T cells at day 77 (P<.05
for both subsets as compared with baseline). We also found
an increase in the sj/β TREC ratio (a reﬂection of thymic
output [18]) from 46 at day 0 to 68.7 at week 12 (day 77),
(mean fold increase, 1.8; P=.06). There was a signiﬁcant
inverse relationship between the change in sj/β TREC ratio
and the CD4 T-cell count at day 0 and the nadir (r =0.40;
P= .01; Spearman’s test) (Figure 3B).
When compared with the T-cell repertoire diversity of his-
torical controls, the repertoire diversity of patients varied from
36% to 83% (median, 63%) at baseline (Figure 3C). Diversity
scores did not increase signiﬁcantly at day 28 (71.5%) or week
12 (64.3%) (Figure 3C). Subjects with normal TCR diversity at
baseline remained in stable condition. Four subjects with a
low baseline diversity score who received rhIL-7 exhibited
increased TCR diversity, from 49%, 55%, 36%, and 50% at
entry to 75%, 61%, and 59% (two patients) at day 28
(Figure 3C), and this change persisted at week 12 (67%, 70%,
52%, and 61%); changes were not noted in a ﬁfth subject who
received placebo. A detailed analysis of the clonotypes from
1 rhIL-7 and 1 placebo recipient is shown in Figure 3D.
Effects of rhIL-7 Administration on HIV Replication
No changes in plasma HIV RNA levels were noted in subjects in
the placebo and 10 µg/kg groups. In contrast, 4 and 2 subjects in
the 20 and 30 µg/kg dose groups, respectively, experienced tran-
sient increases of plasma HIV RNA during or immediately after
rhIL-7 administration (<400 copies/mL in 5 and 1023 copies/
mL in the sixth). No modiﬁcations of highly active ARV therapy
or compliance issues were recognized in these subjects. All sub-
sequent plasma HIV RNA levels remained below detection
through week 52, except in 2 subjects (85 and 52 copies/mL).
Table 2 shows the evolution of the total amount of cell-
associated DNA from HIV. There were no signiﬁcant changes
in intracellular HIV-1 DNA levels when these levels were
expressed per 10
6 PBMC or 10
6 CD4 T cells, irrespective of
the treatment group at week 12 (Table 2). In contrast, when
expressed as log10 copies per milliliter of blood, HIV-1 DNA
signiﬁcantly increased in subjects treated with 20 µg/kg
(median change, 0.4 log10 copies/mL, P=.03 compared with
day 0) or 30 µg/kg (median change, 0.5 log10 copies/mL;
P= .006 compared with day 0).
Safety, Tolerability, and Pharmacokinetics of rhIL-7
At 10 or 20 µg/kg, rhIL-7 was well tolerated. At 30 µg/kg,
dose-limiting toxicity was observed in 2 subjects, one with a
transient grade 3 alanine aminotransferase increase and the
other with a grade 2 rash. No neutralizing anti–IL-7 antibod-
ies were detected. The pharmacokinetic analysis showed loss
of the linear relationship between the area under the curve
and dose at 30 µg/kg (Supplementary Figure 4).
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This study was designed to identify a well-tolerated dose of
rhIL-7 that would achieve the main desirable biologic effect of
IL-7, namely, expansion of the CD4 T-cell pool in HIV-1–
infected subjects. We show substantial and sustained CD4 T-cell
expansions for as long as 1 year after IL-7 treatment, decreases
in the proportions of PD-1
+ T cells, and improved thymopoi-
esis with broadening of the T-cell repertoire in a few subjects.
IL-7 consistently increases circulating T cells in HIV-
infected patients, as was shown with previous formulations [12]
and different schedules of administration [26]. The new
formulation of rhIL-7 (CYT107) given as a cycle of 3 weekly
injections led to a safe and signiﬁcant increase in circulating
Figure 2. Cycling of CD4 and CD8 T-cell subsets in response to recombinant human interleukin 7 (rhIL-7). A, Flow cytometry was used to determine Ki-67
expression in T-cell subsets. Increased naive, central memory (CM), and effector memory T-cell cycling was seen on day 7 (pooled rhIL-7 groups compared
with placebo, P<.001), returning to baseline by day 28 (median, Quarter 1–Quarter 3). The increase was not dose dependent and occurred in both CD4 and
CD8 subsets. B, PD-1 expression decreased on both CD4 and CD8 T cells 28 days after 20 and 30 µg/kg rhIL-7 administration (P<.05 for each). The decrease
persisted until day 77 (P<.0 5).C, CM subsets showed decreased expression of PD-1. Abbreviations: CM, central memory; EM, effector memory; N, naive.
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activity, we identiﬁed the 20 µg/kg dose as ideal for future
studies.
HIV infection is characterized by a progressive depletion of
CD4 T cells due to direct killing, decreased survival of activat-
ed cells, and an impairment of thymic production and naive
Figure 3. Recombinant human interleukin 7 (rhIL-7) therapy increases numbers of naive and recent thymic emigrants (RTE) CD4 T cells and broadens the
T-cell receptor (TCR) repertoire in a few subjects. Data shown are for subjects who received 3 doses of rhIL-7 at 20 or 30 µg/kg. A, Thymic activity was
evaluated using the sj/β T-cell receptor excision circles (TREC) ratio. Treatment with rhIL-7 increased the number of naive and RTE cells in the peripheral
blood on day 77 (P<.05, 20 and 30 µg/kg pooled data). The sj/β TREC ratio tended to increase (P=.06, pooled data for 20 and 30 µg/kg). B, The CD4 T-
cell count at day 0 and CD4 nadir were associated with a change in the sj/β TREC ratio between days 0 and 77 (P=.01; Spearman’s test). C, Subjects
with lower CD4 T-cell counts experienced greater increases in thymopoiesis after rhIL-7 treatment. TCR repertoire diversity was assessed by quantifying all
possible combinations between Vβ and Jβ segments. Shaded area represents range of diversity in historical controls. Diversity increased in all rhIL-7–
treated subjects with diversity below the normal range but not signiﬁcantly for the treated groups overall. D, Distribution of peaks for each Vβ-Jβ rearrange-
ment for a placebo-treated and a rhIL-7–treated patient. Abbreviations: RTE, recent thymic emigrant; TREC, T-cell reception excision circle.
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predominantly the naive and central memory CD4 and CD8
T-cell subsets. Cellular proliferation, as indicated by Ki-67
staining, is probably a major mechanism. Although difﬁcult to
measure in vivo, improved T-cell survival due to rhIL-7 could
not be ruled out. Such an effect was suggested by the de-
creased expression of the exhaustion markers (PD-1) on T
cells and transient increases in Bcl-2 expression, as shown in
the current study and elsewhere in cancer patients [15].
A novel aspect of the present study was the characterization
of the naive T-cell compartment through phenotypic and mo-
lecular measurements. Our ﬁndings of an increase in RTE and
sj/β TREC were compatible with an effect of rhIL-7 on thymic
output and the production and/or expansion of a younger cell
population (eg, naive T cells). We also found changes in the
TCR repertoire in a few subjects with the lowest TCR diversity
at entry. These observations require validation in additional
patients and with a long-term follow-up. Although in the
current study we cannot relate these phenotypic and molecu-
lar changes to a restoration of T-cell function, an earlier study
by our group has shown that IL-7–expanded CD4 T cells
respond well in vitro to mitogens, recall antigens, and HIV
peptides [22]. Similar observations have been made among pa-
tients with cancer who received rhIL-7 [15].
Recent experience with IL-2 therapy in HIV-infected patients
shows that an increase in CD4 T cells does not necessarily
confer a clinical beneﬁt. Analyses of IL-2-expanded cells have
shown a predominant expansion of CD25 T cells [28]w i t ha
long half-life [29] that share molecular and functional charac-
teristics of Tregs [24]. In contrast, we ﬁnd that most expanded
CD4 T cells in rhIL-7–treated subjects did not exhibit Treg fea-
tures, resulting in a relative decrease in Tregs within the total
CD4 T-cell population. Other important differences between
IL-2 and IL-7 are the concomitant expansion of CD8 T cells,
the improved safety proﬁle, and the pharmacokinetic character-
istics of rhIL-7 that could make weekly injections feasible [24].
To date, the long-term effects and safety of rhIL-7 are
unknown. In previous studies of rhIL-7, transient elevations in
plasma HIV RNA levels were noted. A recent study suggested
that the population of cells that harbor HIV DNA may be tar-
geted and expanded by IL-7 [30]. In the present study, about
1 in 4 subjects experienced a transient increase in plasma HIV
RNA levels, and though there was no increase in the propor-
tion of cells containing HIV DNA, the concentration of HIV
DNA per milliliter of blood increased. Although statistically
signiﬁcant, the clinical relevance of this observation remains
to be determined and will be evaluated in future studies.
From a clinical perspective, rhIL-7 may prove to be an attrac-
tive therapeutic adjuvant in HIV disease. If shown to be safe in
longer-term studies, repeated administration of rhIL-7 may
help patients reach and sustain normal circulating CD4 T-cell
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298 ￿ CID 2012:55 (15 July) ￿ Lévy et alcounts. Several epidemiologic studies have indicated that the
circulating CD4 T-cell count is an important predictor of
morbidity including cardiovascular, malignant, renal and
hepatic disease in HIV infection even in patients with con-
trolled viremia receiving ARV therapy [31–33]. As noted above,
recent experience indicates that the circulating CD4 T-cell
count in the setting of cytokine-based therapy of HIV disease
may not be a valid predictor of clinical beneﬁt[ 22]. Therefore,
to conﬁrm clinical utility, clinical trials will need to focus on
clinical end points to determine whether the promising biologic
effects of IL-7 can be translated into clinical beneﬁt.
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